Epidemiologic Study Evaluating Infections in Elderly Patients

• Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer (Industry)
• Overall Status: Completed
• CT.gov ID: NCT00900952
• Collaborator: (none)
• Enrollment: 240
• Location: 1
• Duration (Months): 3
• Patients Per Site Per Month: 79.4

Study Details

Study Description

Brief Summary

The purpose of this observational study is to assess the prevalence and demographic and clinical characteristics of infections in elderly people admitted to Internal Medicine wards in Spain, as well as the etiology and resistance pattern for the main causal agents, and outcome.

Condition or Disease	Intervention/Treatment	Phase
Infection	Other: Clinical record review

Study Design

• Study Type: Observational
• Actual Enrollment: 240 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Epidemiologic Study of Infections in Elderly Patients
• Study Start Date: Mar 1, 2009
• Actual Primary Completion Date: Jun 1, 2009
• Actual Study Completion Date: Jun 1, 2009

Arms and Interventions

Arm	Intervention/Treatment
1 Infected elderly patients	Other: Clinical record review

Outcome Measures

Primary Outcome Measures

1. Prevalence of each kind of infection will be measured from a descriptive point of view, using relative and absolute frequencies. [5 months]

Secondary Outcome Measures

1. Study the etiology and resistance pattern for the main causal agents. [5 months]

2. Describe the demographic features, co-morbidities, concomitant treatment and outcome of patients. [5 months]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 65 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion criteria:

• Patients > 65 years of age that are hospitalized in an Internal Medicine ward and have an active infection (skin and soft tissue, intra-abdominal, or respiratory infections) from the community that needs antibiotic treatment

• Patients must have at least one sample processed for microbiological diagnosis

Exclusion criteria:

• COPD exacerbation

• Urinary tract infections

• Hospital acquired infections

• Other infections not in inclusion criteria

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1		Mataró	Barcelona	Spain	08304

Sponsors and Collaborators

• Wyeth is now a wholly owned subsidiary of Pfizer

Investigators

• Study Director: Medical Monitor, Wyeth is now a wholly owned subsidiary of Pfizer

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• ClinicalTrials.gov Identifier: NCT00900952
• Other Study ID Numbers: 3074X1-4489
• First Posted: May 13, 2009
• Last Update Posted: Oct 9, 2009
• Last Verified: Oct 1, 2009

• Additional relevant MeSH terms: Infections; Communicable Diseases

Study Results

No Results Posted as of Oct 9, 2009